drugset / Trial / NCT01865318

Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes

NCT01865318

Phase 1 Completed 36 enrolled Novo Nordisk A/S
RandomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) of insulin degludec (insulin 454), an explorative formulation, not similar to the proposed commercial formulation, under single-dose and steady-state conditions in male subjects with type 1 diabetes.

Timeline

Start
2006-09
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin degludec Protein / enzyme biologic Subcutaneous